The sterile compounding pharmacies market size has grown strongly in recent years. It will grow from $5.62 billion in 2025 to $5.98 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to growth in injectable therapies, hospital pharmacy demand, regulatory enforcement, oncology drug compounding, specialty medication needs.
The sterile compounding pharmacies market size is expected to see strong growth in the next few years. It will grow to $7.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to biologic drug growth, personalized injectable therapies, hospital capacity constraints, automation adoption, regulatory standard evolution. Major trends in the forecast period include outsourcing of sterile compounding, advanced cleanroom technologies, automation in compounding processes, batch-level traceability, compliance-driven investments.
The growing demand for personalized medicine is expected to drive growth in the sterile compounding pharmacies market in the coming years. Personalized medicine involves preventing, diagnosing, or treating diseases using information about an individual’s genes or proteins. Sterile compounding pharmacies are critical in providing customized medications in a sterile environment, ensuring treatments are tailored to patients’ specific needs while minimizing the risk of intolerance to certain doses or drug compounds. This approach improves treatment outcomes, patient satisfaction, and adherence to therapy. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a substantial increase from six approvals in 2022. Therefore, the rising demand for personalized medicine is fueling growth in the sterile compounding pharmacies market.
Leading companies in the sterile compounding pharmacies market are adopting technological innovations such as robotic automation to improve the safety, efficiency, and scalability of compounding processes. Robotic automation systems integrate advanced monitoring, verification, and labeling technologies to ensure regulatory compliance and maintain product quality. For instance, in March 2023, Omnicell Inc., a US-based healthcare technology company, launched the IVX Station, a robotic compounding system that automates sterile compounding in an ISO Class 5 environment. The system includes continuous monitoring of temperature, humidity, and particles, advanced vision systems, gravimetric verification, auto-labeling, and automated application of tamper-evident syringe caps. Its cloud-based formulation library is continuously updated, providing scalable access to the latest authorized formulations and supporting safe, efficient, and high-volume pharmacy operations.
In October 2025, Revelation Pharma Corp., a US-based compounding pharmacy network, acquired Acacia Apothecary & Wellness for an undisclosed amount. Through this acquisition, Revelation Pharma aims to expand its national compounding network, enhance its sterile and non-sterile compounding capabilities, broaden its wellness product offerings, and strengthen its expertise in personalized pharmaceutical solutions. Acacia Apothecary & Wellness, based in the US, specializes in customized medications and holistic wellness products.
Major companies operating in the sterile compounding pharmacies market are B. Braun SE, PharMerica Corporation, Fagron Group BV, QuVa Pharma Inc., NewCo Pharma GmbH, Medisca, PharMEDium Healthcare Holdings Inc., Central Admixture Pharmacy Services (CAPS), SandsRx LLC, LeeSar Inc., Avella Specialty Pharmacy, Stokes Pharmacy Inc., Imprimis Pharmaceuticals Inc., Wells Pharmacy Network LLC, McGuff Compounding Pharmacy Services Inc., Potter's House Apothecary Inc., Pharos Innovations LLC, Triangle Compounding Pharmacy Inc., Valor Compounding Pharmacy Inc., Pace Pharmacy, PenCol Specialty Pharmacy LLC, Pavilion Compounding Pharmacy LLC, Olympia Pharmacy, MedisourceRx, Stat RX Pharmacy, Rx3 Compounding Pharmacy, Atlas Pharmaceuticals Co. Ltd., ReNue Rx, Premier Pharmacy Labs Inc., Absolute Pharmacy Inc.
North America was the dominant region in the sterile compounding pharmacies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile compounding pharmacies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sterile compounding pharmacies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have increased costs in the sterile compounding pharmacies market by raising prices for imported active pharmaceutical ingredients, sterile containers, filtration systems, and compounding equipment. Pharmacies in Asia-Pacific and Europe are most affected due to reliance on international pharmaceutical and equipment suppliers. These higher costs can increase the price of customized medications. However, tariffs are encouraging domestic sourcing of ingredients and compounding tools, strengthening supply reliability.
The sterile compounding pharmacies market research report is one of a series of new reports that provides sterile compounding pharmacies market statistics, including sterile compounding pharmacies industry global market size, regional shares, competitors with a sterile compounding pharmacies market share, detailed sterile compounding pharmacies market segments, market trends and opportunities, and any further data you may need to thrive in the sterile compounding pharmacies industry. This sterile compounding pharmacies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sterile compounding pharmacies are specialized facilities that prepare customized medications in a sterile environment, providing tailored treatments to meet individual patient needs. This is particularly beneficial for patients who are intolerant to a specific commercial dose or an ingredient in standard formulations. Compounding allows patients to receive medications with customized doses and formulations that remove non-essential or undesirable components.
The main products offered by sterile compounding pharmacies include injectables, nasal, ocular, and otic medications. Injectables are drug formulations designed to be administered using a needle and syringe. These pharmacies provide services such as customization, patient-specific dosing, and elimination of intolerable components, ensuring the safety, sterility, and quality of injectable medications tailored to patient requirements. These products are used across therapeutic areas including hormone replacement therapy, pain management, dermatology, oncology, hematology, dental care, and others. They can be administered intravenously, intramuscularly, or subcutaneously and serve end users such as adults, pediatrics, geriatrics, and veterinary patients.
The sterile compounding pharmacies market consists of sales of injectable drugs and infusions created in an environment free from microorganisms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The sterile compounding pharmacies market size is expected to see strong growth in the next few years. It will grow to $7.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to biologic drug growth, personalized injectable therapies, hospital capacity constraints, automation adoption, regulatory standard evolution. Major trends in the forecast period include outsourcing of sterile compounding, advanced cleanroom technologies, automation in compounding processes, batch-level traceability, compliance-driven investments.
The growing demand for personalized medicine is expected to drive growth in the sterile compounding pharmacies market in the coming years. Personalized medicine involves preventing, diagnosing, or treating diseases using information about an individual’s genes or proteins. Sterile compounding pharmacies are critical in providing customized medications in a sterile environment, ensuring treatments are tailored to patients’ specific needs while minimizing the risk of intolerance to certain doses or drug compounds. This approach improves treatment outcomes, patient satisfaction, and adherence to therapy. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a substantial increase from six approvals in 2022. Therefore, the rising demand for personalized medicine is fueling growth in the sterile compounding pharmacies market.
Leading companies in the sterile compounding pharmacies market are adopting technological innovations such as robotic automation to improve the safety, efficiency, and scalability of compounding processes. Robotic automation systems integrate advanced monitoring, verification, and labeling technologies to ensure regulatory compliance and maintain product quality. For instance, in March 2023, Omnicell Inc., a US-based healthcare technology company, launched the IVX Station, a robotic compounding system that automates sterile compounding in an ISO Class 5 environment. The system includes continuous monitoring of temperature, humidity, and particles, advanced vision systems, gravimetric verification, auto-labeling, and automated application of tamper-evident syringe caps. Its cloud-based formulation library is continuously updated, providing scalable access to the latest authorized formulations and supporting safe, efficient, and high-volume pharmacy operations.
In October 2025, Revelation Pharma Corp., a US-based compounding pharmacy network, acquired Acacia Apothecary & Wellness for an undisclosed amount. Through this acquisition, Revelation Pharma aims to expand its national compounding network, enhance its sterile and non-sterile compounding capabilities, broaden its wellness product offerings, and strengthen its expertise in personalized pharmaceutical solutions. Acacia Apothecary & Wellness, based in the US, specializes in customized medications and holistic wellness products.
Major companies operating in the sterile compounding pharmacies market are B. Braun SE, PharMerica Corporation, Fagron Group BV, QuVa Pharma Inc., NewCo Pharma GmbH, Medisca, PharMEDium Healthcare Holdings Inc., Central Admixture Pharmacy Services (CAPS), SandsRx LLC, LeeSar Inc., Avella Specialty Pharmacy, Stokes Pharmacy Inc., Imprimis Pharmaceuticals Inc., Wells Pharmacy Network LLC, McGuff Compounding Pharmacy Services Inc., Potter's House Apothecary Inc., Pharos Innovations LLC, Triangle Compounding Pharmacy Inc., Valor Compounding Pharmacy Inc., Pace Pharmacy, PenCol Specialty Pharmacy LLC, Pavilion Compounding Pharmacy LLC, Olympia Pharmacy, MedisourceRx, Stat RX Pharmacy, Rx3 Compounding Pharmacy, Atlas Pharmaceuticals Co. Ltd., ReNue Rx, Premier Pharmacy Labs Inc., Absolute Pharmacy Inc.
North America was the dominant region in the sterile compounding pharmacies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sterile compounding pharmacies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the sterile compounding pharmacies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have increased costs in the sterile compounding pharmacies market by raising prices for imported active pharmaceutical ingredients, sterile containers, filtration systems, and compounding equipment. Pharmacies in Asia-Pacific and Europe are most affected due to reliance on international pharmaceutical and equipment suppliers. These higher costs can increase the price of customized medications. However, tariffs are encouraging domestic sourcing of ingredients and compounding tools, strengthening supply reliability.
The sterile compounding pharmacies market research report is one of a series of new reports that provides sterile compounding pharmacies market statistics, including sterile compounding pharmacies industry global market size, regional shares, competitors with a sterile compounding pharmacies market share, detailed sterile compounding pharmacies market segments, market trends and opportunities, and any further data you may need to thrive in the sterile compounding pharmacies industry. This sterile compounding pharmacies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Sterile compounding pharmacies are specialized facilities that prepare customized medications in a sterile environment, providing tailored treatments to meet individual patient needs. This is particularly beneficial for patients who are intolerant to a specific commercial dose or an ingredient in standard formulations. Compounding allows patients to receive medications with customized doses and formulations that remove non-essential or undesirable components.
The main products offered by sterile compounding pharmacies include injectables, nasal, ocular, and otic medications. Injectables are drug formulations designed to be administered using a needle and syringe. These pharmacies provide services such as customization, patient-specific dosing, and elimination of intolerable components, ensuring the safety, sterility, and quality of injectable medications tailored to patient requirements. These products are used across therapeutic areas including hormone replacement therapy, pain management, dermatology, oncology, hematology, dental care, and others. They can be administered intravenously, intramuscularly, or subcutaneously and serve end users such as adults, pediatrics, geriatrics, and veterinary patients.
The sterile compounding pharmacies market consists of sales of injectable drugs and infusions created in an environment free from microorganisms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Sterile Compounding Pharmacies Market Characteristics
3. Sterile Compounding Pharmacies Market Supply Chain Analysis
4. Global Sterile Compounding Pharmacies Market Trends and Strategies
5. Sterile Compounding Pharmacies Market Analysis of End Use Industries
7. Global Sterile Compounding Pharmacies Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Sterile Compounding Pharmacies Total Addressable Market (TAM) Analysis for the Market
9. Sterile Compounding Pharmacies Market Segmentation
10. Sterile Compounding Pharmacies Market Regional and Country Analysis
11. Asia-Pacific Sterile Compounding Pharmacies Market
12. China Sterile Compounding Pharmacies Market
13. India Sterile Compounding Pharmacies Market
14. Japan Sterile Compounding Pharmacies Market
15. Australia Sterile Compounding Pharmacies Market
16. Indonesia Sterile Compounding Pharmacies Market
17. South Korea Sterile Compounding Pharmacies Market
18. Taiwan Sterile Compounding Pharmacies Market
19. South East Asia Sterile Compounding Pharmacies Market
20. Western Europe Sterile Compounding Pharmacies Market
21. UK Sterile Compounding Pharmacies Market
22. Germany Sterile Compounding Pharmacies Market
23. France Sterile Compounding Pharmacies Market
24. Italy Sterile Compounding Pharmacies Market
25. Spain Sterile Compounding Pharmacies Market
26. Eastern Europe Sterile Compounding Pharmacies Market
27. Russia Sterile Compounding Pharmacies Market
28. North America Sterile Compounding Pharmacies Market
29. USA Sterile Compounding Pharmacies Market
30. Canada Sterile Compounding Pharmacies Market
31. South America Sterile Compounding Pharmacies Market
32. Brazil Sterile Compounding Pharmacies Market
33. Middle East Sterile Compounding Pharmacies Market
34. Africa Sterile Compounding Pharmacies Market
36. Sterile Compounding Pharmacies Market Competitive Landscape and Company Profiles
37. Sterile Compounding Pharmacies Market Other Major and Innovative Companies
40. Sterile Compounding Pharmacies Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Sterile Compounding Pharmacies Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses sterile compounding pharmacies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sterile compounding pharmacies? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sterile compounding pharmacies market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Injectables; Nasal; Ocular; Otic2) By Therapeutic Area: Hormone Replacement Therapy; Pain Management; Dermatology; Oncology; Hematology; Dental; Other Therapeutic Areas
3) By Route Of Administrations: Intravenous; Intramuscular; Subcutaneous
4) By End-Users: Adults; Pediatrics; Geriatrics; Veterinary
Subsegments:
1) By Injectables: Sterile Solutions; Sterile Suspensions; Sterile Powders For Reconstitution2) By Nasal: Nasal Sprays; Nasal Solutions; Nasal Gels
3) By Ocular: Ophthalmic Solutions; Ophthalmic Suspensions; Ocular Inserts
4) By Otic: Otic Solutions; Otic Suspensions; Otic Gels
Companies Mentioned: B. Braun SE; PharMerica Corporation; Fagron Group BV; QuVa Pharma Inc.; NewCo Pharma GmbH; Medisca; PharMEDium Healthcare Holdings Inc.; Central Admixture Pharmacy Services (CAPS); SandsRx LLC; LeeSar Inc.; Avella Specialty Pharmacy; Stokes Pharmacy Inc.; Imprimis Pharmaceuticals Inc.; Wells Pharmacy Network LLC; McGuff Compounding Pharmacy Services Inc.; Potter's House Apothecary Inc.; Pharos Innovations LLC; Triangle Compounding Pharmacy Inc.; Valor Compounding Pharmacy Inc.; Pace Pharmacy; PenCol Specialty Pharmacy LLC; Pavilion Compounding Pharmacy LLC; Olympia Pharmacy; MedisourceRx; Stat RX Pharmacy; Rx3 Compounding Pharmacy; Atlas Pharmaceuticals Co. Ltd.; ReNue Rx; Premier Pharmacy Labs Inc.; Absolute Pharmacy Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Sterile Compounding Pharmacies market report include:- B. Braun SE
- PharMerica Corporation
- Fagron Group BV
- QuVa Pharma Inc.
- NewCo Pharma GmbH
- Medisca
- PharMEDium Healthcare Holdings Inc.
- Central Admixture Pharmacy Services (CAPS)
- SandsRx LLC
- LeeSar Inc.
- Avella Specialty Pharmacy
- Stokes Pharmacy Inc.
- Imprimis Pharmaceuticals Inc.
- Wells Pharmacy Network LLC
- McGuff Compounding Pharmacy Services Inc.
- Potter's House Apothecary Inc.
- Pharos Innovations LLC
- Triangle Compounding Pharmacy Inc.
- Valor Compounding Pharmacy Inc.
- Pace Pharmacy
- PenCol Specialty Pharmacy LLC
- Pavilion Compounding Pharmacy LLC
- Olympia Pharmacy
- MedisourceRx
- Stat RX Pharmacy
- Rx3 Compounding Pharmacy
- Atlas Pharmaceuticals Co. Ltd.
- ReNue Rx
- Premier Pharmacy Labs Inc.
- Absolute Pharmacy Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.98 Billion |
| Forecasted Market Value ( USD | $ 7.78 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
